文献速递泌尿男性生殖肿瘤

睾酮替代治疗与有利风险及侵袭性前列腺癌风险

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2017-03-13

该研究基于瑞典国家前列腺癌登记库的巢式病例对照研究,纳入2009至2012年诊断的38570例前列腺癌患者及192838名年龄匹配的无前列腺癌男性,分析睾酮替代治疗(TRT)与前列腺癌风险的关系。结果显示TRT与总体前列腺癌风险无关(OR 1.03,95%CI 0.90-1.17),但与有利风险前列腺癌风险升高相关(OR 1.35,95%CI 1.16-1.56),与侵袭性前列腺癌风险降低相关(OR 0.50,95%CI 0.37-0.67);作者认为有利风险癌的早期增加提示检测偏倚,而侵袭性癌风险降低是新发现,需进一步研究。

要点

  • TRT与总体前列腺癌风险无关(OR 1.03,95%CI 0.90-1.17)。
  • TRT与有利风险前列腺癌风险升高相关(OR 1.35,95%CI 1.16-1.56),治疗第一年内即出现(OR 1.61,95%CI 1.10-2.34)。
  • TRT与侵袭性前列腺癌风险降低相关(OR 0.50,95%CI 0.37-0.67),治疗超过1年后出现(OR 0.44,95%CI 0.32-0.61)。

核心结论

  • 接受TRT的患者中有利风险前列腺癌的早期增加提示检测偏倚,而侵袭性前列腺癌风险降低是新发现,需进一步研究。

研究设计与样本

  • 在瑞典国家前列腺癌登记库中进行的巢式病例对照研究,纳入2009至2012年诊断的全部38570例前列腺癌病例和192838名年龄匹配的无前列腺癌男性。
  • 采用多变量条件逻辑回归分析TRT与前列腺癌(总体、有利风险和侵袭性)风险之间的关联。

主要发现

  • 284例前列腺癌患者(1%)和1378例对照(1%)曾开具TRT处方。
  • 多变量分析未发现TRT与总体前列腺癌风险相关(OR 1.03;95%CI 0.90-1.17)。
  • 接受TRT的患者有利风险前列腺癌更多(OR 1.35;95%CI 1.16-1.56),侵袭性前列腺癌风险更低(OR 0.50;95%CI 0.37-0.67)。
  • 有利风险前列腺癌的增加在TRT第一年内即观察到(OR 1.61;95%CI 1.10-2.34),而侵袭性疾病风险降低在TRT超过1年后观察到(OR 0.44;95%CI 0.32-0.61)。
  • 调整既往活检结果作为诊断活动指标后,TRT仍与有利风险前列腺癌更多及侵袭性前列腺癌风险更低显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The association between exposure to testosterone replacement therapy (TRT) and prostate cancer risk is controversial. The objective was to examine this association through nationwide, population-based registry data. Methods We performed a nested case-control study in the National Prostate Cancer Register of Sweden, which includes all 38,570 prostate cancer cases diagnosed from 2009 to 2012, and 192,838 age-matched men free of prostate cancer. Multivariable conditional logistic regression was used to examine associations between TRT and risk of prostate cancer (overall, favorable, and aggressive). Results Two hundred eighty-four patients with prostate cancer (1%) and 1,378 control cases (1%) filled prescriptions for TRT. In multivariable analysis, no association was found between TRT and overall prostate cancer risk (odds ratio [OR], 1.03; 95% CI, 0.90 to 1.17). However, patients who received TRT had more favorable-risk prostate cancer (OR, 1.35; 95% CI, 1.16 to 1.56) and a lower risk of aggressive prostate cancer (OR, 0.50; 95% CI, 0.37 to 0.67). The increase in favorable-risk prostate cancer was already observed within the first year of TRT (OR, 1.61; 95% CI, 1.10 to 2.34), whereas the lower risk of aggressive disease was observed after > 1 year of TRT (OR, 0.44; 95% CI, 0.32 to 0.61). After adjusting for previous biopsy findings as an indicator of diagnostic activity, TRT remained significantly associated with more favorable-risk prostate cancer and lower risk of aggressive prostate cancer. Conclusion The early increase in favorable-risk prostate cancer among patients who received TRT suggests a detection bias, whereas the decrease in risk of aggressive prostate cancer is a novel finding that warrants further investigation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Loeb S, Folkvaljon Y, Damber JE, et al. Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer. J Clin Oncol. 2017. PMID: 28447913. doi:10.1200/JCO.2016.69.5304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。